A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Clinical trial NCT05064059 · COMPLETED
Trial details
- NCT number
- NCT05064059
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-10
- Primary completion
- 2024-08-15
- Enrollment
- 441
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.